Conference Call with Dr. Lal Pathlabs Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Healthcare Services company Dr. Lal Pathlabs announced Q4FY25 results Revenue: Rs 603 crore compared to Rs 545 crore during Q4FY24, change 10.5%. EBITDA: Rs 169 crore compared to Rs 145 crore during Q4FY24, change 16.9%. EBITDA margin: 28.1% for Q4FY25. PAT: Rs 156 crore compared to Rs 86 crore during Q4FY24, change 81.4%. PAT margin: 25.8% for Q4FY25. Fourth Interim Dividend of Rs 6 per share for FY25. Result PDF
Conference Call with Dr. Lal Pathlabs Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Healthcare Services company Dr. Lal Pathlabs announced Q3FY25 results Revenue increased by 10.7% from Rs 597 crore in Q3FY25 to Rs 539 crore in Q3FY24.. EBITDA increased by 9.6% from Rs 154 crore in Q3FY25 to Rs 141 crore in Q3FY24, with a margin of 25.8%. PAT increased by 19.3% from Rs 98 crore in Q3FY25 to Rs 82 crore in Q3FY24, with a margin for of 16.4%. Third Interim Dividend of Rs. 6 per share for FY25. Result PDF